VWM
CRDF icon

Vigilare Wealth Management’s Cardiff Oncology CRDF Stock Holding History

Vigilare Wealth Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$67K – 197
2021
Q2 		$67K Buy
+10,000
New +$84.8K 0.04% 205

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vigilare Wealth Management's CRDF Position: Q3 2021 in Review

Vigilare Wealth Management sold out of Cardiff Oncology (CRDF) in Q3 2021, closing a stake of 10,000 shares — an estimated $67K sold.

Vigilare Wealth Management first reported a position in CRDF in Q2 2021 and held it in 1 quarter. The position peaked at $67K in Q2 2021. 94 funds tracked by Wall St. Rank hold CRDF as of Q3 2021.

  • Vigilare Wealth Management reported no remaining Cardiff Oncology position as of Q3 2021 after selling out during the quarter.
  • Vigilare Wealth Management sold 10,000 Cardiff Oncology shares in Q3 2021, an estimated $67K.
  • Vigilare Wealth Management first reported a position in Cardiff Oncology in Q2 2021 and held it in 1 quarter.
  • Vigilare Wealth Management's Cardiff Oncology position peaked at $67K in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2021.

Based on Vigilare Wealth Management's 13F filing for Q3 2021, filed 19 Oct 2021.